Edition:
India

Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

22.12USD
10:35pm IST
Change (% chg)

$0.30 (+1.37%)
Prev Close
$21.82
Open
$21.91
Day's High
$22.94
Day's Low
$21.74
Volume
37,525
Avg. Vol
78,691
52-wk High
$24.20
52-wk Low
$3.40

Latest Key Developments (Source: Significant Developments)

Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102
Saturday, 19 May 2018 

May 18 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE 1/2 GENE THERAPY TRIAL OF RP-L102 IN PATIENTS WITH FANCONI ANEMIA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) ANNUAL MEETING.ROCKET PHARMACEUTICALS - CONTINUED CLINICAL EVIDENCE DEMONSTRATES RP-L102 CAN RESTORE BONE MARROW FUNCTION OF FANCONI ANEMIA PATIENTS WITHOUT CONDITIONING.ROCKET PHARMACEUTICALS INC - ALL PATIENTS DEMONSTRATED CONTINUED IMPROVEMENT IN ENGRAFTMENT FOLLOWING ADMINISTRATION OF RP-L102 IN TRIAL.ROCKET PHARMACEUTICALS INC - NO SERIOUS DRUG-RELATED ADVERSE EVENTS HAVE BEEN OBSERVED TO DATE IN TRIAL.ROCKET PHARMACEUTICALS INC - ADDITIONAL PATIENT DATA FROM FA PROGRAM IS EXPECTED OVER NEXT 12-18 MONTHS.ROCKET PHARMACEUTICALS - ROCKET WILL ENGAGE WITH REGULATORY AUTHORITIES TO PROGRESS RP-L102 TOWARDS A POTENTIAL GLOBAL REGISTRATIONAL STUDY IN 2019.  Full Article

Rocket Pharmaceuticals Prices Public Offering Of Common Stock
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $13.25PER SHARE.  Full Article

Inotek files for preliminary proxy statement for proposed merger with Rocket Pharmaceuticals
Friday, 13 Oct 2017 

Oct 12 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals announces filing of preliminary proxy statement for proposed merger with clinical-stage gene therapy company, Rocket Pharmaceuticals.Inotek Pharmaceuticals Corp - ‍additional first-in-human results from up to three programs expected in 2018​.Inotek Pharmaceuticals Corp - ‍merger is expected to close in Q1 of 2018​.  Full Article

Citadel Advisors LLC reports 6.5 pct passive stake in Inotek Pharmaceuticals Corp
Monday, 29 Aug 2016 

Inotek Pharmaceuticals Corp : Citadel Advisors LLC reports 6.5 percent passive stake in Inotek Pharmaceuticals Corp, as of August 22, 2016 - Sec filing Source - http://bit.ly/2bwMi6x Further company coverage: [ITEK.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Inotek Pharmaceuticals says completion of recruitment phase of Matrx-1
Wednesday, 24 Aug 2016 

Inotek Pharmaceuticals : Announces completion of recruitment phase of Matrx-1, first phase 3 clinical trial of Trabodenoson for glaucoma . Top-line data from Matrx-1 study are expected in december 2016. .Says top-line data from Matrx-1 study are expected in December 2016.  Full Article

Inotek Pharmaceuticals reports Q2 loss per share $0.33
Wednesday, 10 Aug 2016 

Inotek Pharmaceuticals Corp : Inotek Pharmaceuticals Corporation reports second quarter 2016 financial results and operational highlights . Q2 loss per share $0.33 .Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.  Full Article

Inotek announces pricing of $50 mln convertible senior notes
Tuesday, 2 Aug 2016 

Inotek Pharmaceuticals Corp :Inotek pharmaceuticals announces pricing of $50.0 million of 5.75 percent convertible senior notes due 2021.  Full Article

Inotek Pharmaceuticals announces offering of $50 mln of convertible senior notes
Monday, 1 Aug 2016 

Inotek Pharmaceuticals Corp: Inotek Pharmaceuticals announces proposed public offering of $50 million of convertible senior notes due 2021 . To use proceeds from offering to fund continued testing of trabodenoson as a monotherapy and as a fixed-dose ombination with latanoprost .Offering includes grant to underwriters of 30-day option to purchase up to additional $7.5 million aggregate principal amount of notes.  Full Article

Photo

Rocket-control glitch delays launch of NASA's planet-hunting satellite

CAPE CANAVERAL, Fla. An 11th-hour technical glitch prompted SpaceX to postpone its planned launch on Monday of a new NASA space telescope designed to detect worlds beyond our solar system, delaying for at least 48 hours a quest to expand astronomers' known inventory of so-called exoplanets.